Shang et al. [23] demonstrated that FAK deletion/inhibition may block tumor progression and delays mortality of mice with a mesenchymal–epithelial transition factor (c-MET)/β-catenin-driven HCC. This evidence concerns the gene PTK2 and hepatocellular carcinoma.